{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-21-003253","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2021-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.943381+00:00","generated_at":"2026-06-28T17:59:14.636899+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Chemomab shareholders approve CEO Dale Pfost employment terms at special meeting","bullets":["Special meeting held Oct 25, 2021; 42.74% of outstanding shares represented.","Proposal to approve CEO Dr. Dale Pfost's employment terms passed with 96.3M for, 1.2M against.","Pfost was engaged as CEO on September 1, 2021.","Vote satisfied requisite majority under Israeli Companies Law."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-21-003253","json":"https://secwatch.observer/filing/0001178913-21-003253.json","markdown":"https://secwatch.observer/filing/0001178913-21-003253.md","text":"https://secwatch.observer/filing/0001178913-21-003253.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003253/0001178913-21-003253-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003253/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T17:59:14.636899+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}